Illumina names new CEO months after Icahn proxy fight over Grail deal

Illumina names new CEO months after Icahn proxy fight over Grail deal


A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021.

Mike Blake | Reuters

Illumina‘s board on Tuesday named Jacob Thaysen the DNA sequencing company’s new CEO as it tries to rebound from a grinding dispute over its acquisition of cancer test developer Grail.

Thaysen, a 48-year-old longtime executive at medical devices firm Agilent, will step in as CEO on Sept. 25. His nomination comes months after a bitter proxy fight with activist investor Carl Icahn ended with Illumina’s former CEO Francis deSouza resigning despite securing enough votes to stay. 

Illumina closed its $7.1 billion acquisition of Grail in 2021 without first securing approval from antitrust regulators in the U.S. and European Union — a decision that prompted Icahn to seek board seats and push the companies to unwind the deal. 

Shares of Illumina fell more than 5% on Tuesday following the announcement. 

New leadership could help Illumina regain its footing after a rocky past two years. The company’s market value has fallen to roughly $25 billion from around $75 billion in August 2021, the month it closed its acquisition of Grail. 

Thaysen will step in as Illumina fights two orders seeking to block the Grail acquisition: One from the European Commission, the EU’s executive body, and another from the U.S. Federal Trade Commission. 

Illumina has appealed both orders and expects final decisions in late 2023 or early 2024. 

Thaysen will join Illumina after a nearly 10-year tenure at Agilent. He led the analytical instruments division of Agilent since 2018, and served as president of the company’s diagnostics and genomics department from 2014 to 2018. 

He nearly doubled that division’s operating profit during those four years, according to a press release from Illumina. 

“Jacob’s unique combination of deep technological and commercial experience will be a great addition to Illumina,” Stephen MacMillan, the chair of Illumina’s board, said in the release. “He brings a fresh perspective, a demonstrated track record driving profitable growth, and a strong commitment to create value for all of Illumina’s stakeholders.”

Thaysen will take over for Charles Dadswell, who has been serving as Illumina’s interim CEO since June. Dadswell will resume his role as senior vice president and general counsel at Illumina.



Source

Gen Z and social media are helping men’s makeup go mainstream. The beauty industry is trying to capitalize
Business

Gen Z and social media are helping men’s makeup go mainstream. The beauty industry is trying to capitalize

Pixdeluxe | E+ | Getty Images It often starts small. A dab of concealer. A tinted moisturizer. Maybe a brow gel that goes from borrowed to bought. For many men, like Daniel Rankin, makeup has transformed from something taboo into a tool to make them look less tired and more put together. “I remember thinking, […]

Read More
Stellantis scraps Jeep, Chrysler plug-in hybrid vehicles amid EV slowdown, recall
Business

Stellantis scraps Jeep, Chrysler plug-in hybrid vehicles amid EV slowdown, recall

The Camp Jeep outdoor terrain at the New York International Auto Shown on April 16, 2025. Danielle DeVries | CNBC DETROIT — Stellantis is scrapping its plug-in hybrid electric Jeep SUVs and Chrysler minivan amid slowing EV sales, quality issues and weakened federal fuel economy requirements. The automaker on Friday said the decision to end […]

Read More
Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
Business

Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill

Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021.  Smith Collection | Gado | Getty Images Amazon announced Friday it now offers Novo Nordisk‘s Wegovy weight-loss pill through its digital pharmacy. Novo Nordisk began rolling out an oral version of its injectable obesity drug Wegovy in the […]

Read More